4BB vs. FUM, SCLP, FARN, ETX, AVCT, POLB, HVO, TRX, AREC, and OXB
Should you be buying 4basebio stock or one of its competitors? The main competitors of 4basebio include Futura Medical (FUM), Scancell (SCLP), Faron Pharmaceuticals Oy (FARN), e-therapeutics (ETX), Avacta Group (AVCT), Poolbeg Pharma (POLB), hVIVO (HVO), Tissue Regenix Group (TRX), Arecor Therapeutics (AREC), and Oxford Biomedica (OXB). These companies are all part of the "biotechnology" industry.
4basebio (LON:4BB) and Futura Medical (LON:FUM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, community ranking, valuation, dividends, institutional ownership, risk, earnings, analyst recommendations and media sentiment.
4basebio has a net margin of 0.00% compared to Futura Medical's net margin of -299.73%. Futura Medical's return on equity of -66.35% beat 4basebio's return on equity.
Futura Medical has higher revenue and earnings than 4basebio. 4basebio is trading at a lower price-to-earnings ratio than Futura Medical, indicating that it is currently the more affordable of the two stocks.
Futura Medical received 186 more outperform votes than 4basebio when rated by MarketBeat users.
In the previous week, Futura Medical had 1 more articles in the media than 4basebio. MarketBeat recorded 1 mentions for Futura Medical and 0 mentions for 4basebio. 4basebio's average media sentiment score of 0.00 equaled Futura Medical'saverage media sentiment score.
9.1% of 4basebio shares are held by institutional investors. Comparatively, 36.0% of Futura Medical shares are held by institutional investors. 62.2% of 4basebio shares are held by insiders. Comparatively, 32.9% of Futura Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
4basebio has a beta of 1.1, indicating that its share price is 10% more volatile than the S&P 500. Comparatively, Futura Medical has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500.
Summary
Futura Medical beats 4basebio on 9 of the 13 factors compared between the two stocks.
Get 4basebio News Delivered to You Automatically
Sign up to receive the latest news and ratings for 4BB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding 4BB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
4basebio Competitors List
Related Companies and Tools